Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List
1. AUGTYRO included in China's NRDL for ROS1+ NSCLC treatment. 2. NUZYRA and QINLOCK renewals expand patient access in China. 3. Approximately 1,060,600 new lung cancer cases reported in China, 2022. 4. Launch of AUGTYRO expected by end of 2024 in China. 5. Zai Lab emphasizes commitment to addressing medical needs in oncology.